Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9 Normal Saline Clear all

Conditions: Coronary Artery Disease
Interventions: iodixanol; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Vitamin B 12 Deficiency
Interventions: Cyanocobalamin, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cancer
Interventions: Normal Saline Group, Heparin Group; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Shigella sonnei 53G; Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 49 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: West Nile Fever
Interventions: ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 5
States / cities: Phoenix, Arizona • Idaho Falls, Idaho • Lenexa, Kansas + 2 more

Conditions: Grade 1 Endometrial Endometrioid Adenocarcinoma, Grade 2 Endometrial Endometrioid Adenocarcinoma, Complex Atypical Endometrial Hyperplasia
Interventions: Depot medroxyprogesterone acetate, Placebo; Drug · Other
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Osteoarthritis, Knee, Knee Osteoarthritis, Knee Arthritis, Knee Pain Chronic
Interventions: 4 mL injection of Ampion, 4 mL Injection of Placebo; Biological · Drug
Lead sponsor: Ampio Pharmaceuticals. Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 13
States / cities: Birmingham, Alabama • Encinitas, California • Fullerton, California + 10 more

Conditions: Kidney Failure
Interventions: rhC1INH, Saline Solution; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
Interventions: Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib, Placebo Saline Infusion; Biological · Drug · Other
Lead sponsor: CatalYm GmbH; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: Irvine, California • Los Angeles, California • Orange, California + 4 more

Conditions: Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions: placebo, iv sildenafil; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 0 Days to 4 Days
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 20
States / cities: Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more

Conditions: Metastatic Colorectal Carcinoma, Neuropathy
Interventions: BXQ-350, Placebo; Drug · Other
Lead sponsor: Bexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 12
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 9 more

Conditions: Cocaine Addiction
Interventions: lidocaine following cue-induced craving, lidocaine following neutral stimulus, saline; Drug
Lead sponsor: Bryon Adinoff; Other
Eligibility: 25 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hematologic Malignancies
Interventions: Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review; Biological · Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Duarte, California • Miami, Florida • Tampa, Florida + 4 more

Conditions: Colonic Neoplasms
Interventions: Normal (0.9%) saline, HalfLytely; Drug
Lead sponsor: Arya, Vijaypal, M.D., P.C.; Individual
Eligibility: 21 Years to 70 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Middle Village, New York

Conditions: Irritation/Irritant
Interventions: Hypochlorous acid solution 106 mg/L, 0.1% (w/v) Sodium Lauryl Sulfate, 0.9% Physiological Saline, USP; Drug
Lead sponsor: Pulmatrix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Butte, Montana

Conditions: Rheumatoid Arthritis
Interventions: Cimzia, Placebo; Drug
Lead sponsor: Michael Schiff, MD; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 12
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more

Conditions: Sepsis, Kidney Injury, Thiamine Deficiency
Interventions: Thiamine Hydrochloride, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts • Manhasset, New York • New York, New York + 1 more

Conditions: Healthy Volunteers
Interventions: Unfractionated heparin (UFH), Bendavia, Saline (0.9%, sterile, for infusion); Drug
Lead sponsor: Mighty Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Osteoporosis
Interventions: Zoledronic acid, Placebo, Teriparatide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 45 Years to 89 Years · Female only
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 18
States / cities: Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more

Conditions: Acute Myeloid Leukemia
Interventions: Gemtuzumab ozogamicin, Mitoxantrone, Etoposide; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Osteopenia
Interventions: Zoledronic Acid, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Abnormalities, Cardiovascular
Interventions: Volanesorsen, Moxifloxacin, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Skin Irritation
Interventions: Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution o sodium lauryl sulfate (SLS), Saline 0.9%; Drug
Lead sponsor: Ventrus Biosciences, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Diphtheria, Pertussis, Tetanus
Interventions: Placebo, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Durham, North Carolina • Houston, Texas • Seattle, Washington

Search by objective public record fields.

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

Effects of Vitamin B12 Treatment in Singers

Heparin Versus Normal Saline in Peripherally Inserted Central Catheter Lines

Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain

Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy

AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee

RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving

IVIG for Infection Prevention After CAR-T-Cell Therapy

Yoga and Bolus Lukewarm Saline as Rapid Colonoscopy Preparation

21 Day Cumulative Skin Irritation of RUT058-60

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

Thiamine as a Renal Protective Agent in Septic Shock

Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

Pertussis Vaccine in Healthy Pregnant Women